|This article needs additional citations for verification. (March 2010) (Learn how and when to remove this template message)|
An insulin analog is an altered form of insulin, different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycemic control. Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics. Officially, the U.S. Food and Drug Administration (FDA) refers to these as "insulin receptor ligands", although they are more commonly referred to as insulin analogs.
These modifications have been used to create two types of insulin analogs: those that are more readily absorbed from the injection site and therefore act faster than natural insulin injected subcutaneously, intended to supply the bolus level of insulin needed at mealtime (prandial insulin); and those that are released slowly over a period of between 8 and 24 hours, intended to supply the basal level of insulin during the day and particularly at nighttime (basal insulin). The first insulin analog approved for human therapy (insulin Lispro rDNA) was manufactured by Eli Lilly and Company.
Eli Lilly and Company developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter the insulin receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections.
Novo Nordisk created "aspart" and marketed it as NovoLog/NovoRapid (UK-CAN) as a rapid-acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor. This analogue also prevents the formation of hexamers, to create a faster acting insulin. It is approved for use in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection.
Glulisine is rapid acting insulin analog from Sanofi-Aventis, approved for use with a regular syringe, in an insulin pump. Standard syringe delivery is also an option. It is sold under the name Apidra. The FDA-approved label states that it differs from regular human insulin by its rapid onset and shorter duration of action.
Novo Nordisk created insulin detemir and markets it under the trade name Levemir as a long-lasting insulin analogue for maintaining the basal level of insulin. The basal level of insulin may be maintained for up to 20 hours, but the time is affected by the size of the injected dose. This insulin has a high affinity for serum albumin, increasing its duration of action.
This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).
Sanofi-Aventis developed glargine as a longer-lasting insulin analogue, and markets it under the trade name Lantus. It was created by modifying three amino acids. Two positively charged arginine molecules were added to the C-terminus of the B-chain, and they shift the isoelectric point from 5.4 to 6.7, making glargine more soluble at a slightly acidic pH and less soluble at a physiological pH. Replacing the acid-sensitive asparagine at position 21 in the A-chain by glycine is needed to avoid deamination and dimerization of the arginine residue. These three structural changes and formulation with zinc result in a prolonged action when compared with biosynthetic human insulin. When the pH 4.0 solution is injected, most of the material precipitates and is not bioavailable. A small amount is immediately available for use, and the remainder is sequestered in subcutaneous tissue. As the glargine is used, small amounts of the precipitated material will move into solution in the bloodstream, and the basal level of insulin will be maintained up to 24 hours. The onset of action of subcutaneous insulin glargine is somewhat slower than NPH human insulin. It is clear solution as there is no zinc in formula.
Comparison with other insulins
NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin with delayed absorption after subcutaneous injection, used for basal insulin support in diabetes type 1 and type 2. NPH insulins are suspensions that require shaking for reconstitution prior to injection. Many people reported problems when being switched to intermediate acting insulins in the 80s, using NPH formulations of porcine/bovine insulins. Basal insulin analogs were subsequently developed and introduced into clinical practice to achieve more predictable absorption profiles and clinical efficacy.
The amino acid sequence of animal insulins in different mammals may be similar to human insulin (insulin human INN), there is however considerable viability within vertebrate species. Porcine insulin has only a single amino acid variation from the human variety, and bovine insulin varies by three amino acids. Both are active on the human receptor with approximately the same strength. Bovine insulin and porcine insulin may be considered as the first clinically used insulin analogs (naturally occurring, produced by extraction from animal pancreas), at the time when biosynthetic human insulin (insulin human rDNA) was not available. There are extensive reviews on structure-relationship of naturally occurring insulins (phylogenic relationship in animals) and structural modifications. Prior to the introduction of biosynthetic human insulin, insulin derived from sharks was widely used in Japan. Insulin from some species of fish may be also effective in humans. Non-human insulins have caused allergic reactions in some patients related to the extent of purification, formation of non-neutralising antibodies is rarely observed with recombinant human insulin (insulin human rDNA) but allergy may occur in some patients. This may be enhanced by the preservatives used in insulin preparations, or occur as a reaction to the preservative. Biosynthetic insulin (insulin human rDNA) has largely replaced animal insulin.
Before biosynthetic human recombinant analogues were available, porcine insulin was chemically converted into human insulin. Chemical modifications of the amino acid side chains at the N-terminus and/or the C-terminus were made in order to alter the ADME characteristics of the analogue. Semisynthetic insulins were clinically used for some time based on chemical modification of animal insulins, for example Novo Nordisk enzymatically converted porcine insulin into semisynthetic 'human' insulin by removing the single amino acid that varies from the human variety, and chemically adding the human amino acid.
Normal unmodified insulin is soluble at physiological pH. Analogues have been created that have a shifted isoelectric point so that they exist in a solubility equilibrium in which most precipitates out but slowly dissolves in the bloodstream and is eventually excreted by the kidneys. These insulin analogues are used to replace the basal level of insulin, and may be effective over a period of up to 24 hours. However, some insulin analogues, such as insulin detemir, bind to albumin rather than fat like earlier insulin varieties, and results from long-term usage (e.g. more than 10 years) are currently not available but required for assessment of clinical benefit.
Unmodified human and porcine insulins tend to complex with zinc in the blood, forming hexamers. Insulin in the form of a hexamer will not bind to its receptors, so the hexamer has to slowly equilibrate back into its monomers to be biologically useful. Hexameric insulin delivered subcutaneously is not readily available for the body when insulin is needed in larger doses, such as after a meal (although this is more a function of subcutaneously administered insulin, as intravenously dosed insulin is distributed rapidly to the cell receptors, and therefore, avoids this problem). Zinc combinations of insulin are used for slow release of basal insulin. Basal insulin support is required throughout the day representing about 50% of daily insulin requirement, the insulin amount needed at mealtime makes up for the remaining 50%. Non hexameric insulins (monomeric insulins) were developed to be faster acting and to replace the injection of normal unmodified insulin before a meal. There are phylogenetic examples for such monomeric insulins in animals.
All insulin analogs must be tested for carcinogenicity, as insulin engages in cross-talk with IGF pathways, which can cause abnormal cell growth and tumorigenesis. Modifications to insulin always carry the risk of unintentionally enhancing IGF signalling in addition to the desired pharmacological properties. There has been concern with the mitogenic activity and the potential for carcinogenicity of glargine. Several epidemiological studies have been performed to address these issues. Recent study result of the 6.5 years Origin study with glargine have been published.
A meta-analysis in 2007 of numerous randomized controlled trials by the international Cochrane Collaboration found "only a minor clinical benefit of treatment with long-acting insulin analogues (including two studies of insulin detemir) for patients with diabetes mellitus type 2" while others have examined the same issue in type 1 diabetes. Subsequent meta-analyses undertaken in a number of countries and continents have confirmed Cochrane's findings.
In 2007, Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector (IQWiG) reached a similar conclusion based on absence of conclusive double-blind comparative studies. In its report, IQWiG concluded that there is currently "no evidence" available of the superiority of rapid-acting insulin analogs over synthetic human insulins in the treatment of adult patients with type 1 diabetes. Many of the studies reviewed by IQWiG were either too small to be considered statistically reliable and, perhaps most significantly, none of the studies included in their widespread review were blinded, the gold-standard methodology for conducting clinical research. However, IQWiG's terms of reference explicitly disregard any issues which cannot be tested in double-blind studies, for example a comparison of radically different treatment regimes. IQWiG is regarded with skepticism by some doctors in Germany, being seen merely as a mechanism to reduce costs. But the lack of study blinding does increase the risk of bias in these studies. The reason this is important is because patients, if they know they are using a different type of insulin, might behave differently (such as testing blood glucose levels more frequently, for example), which leads to bias in the study results, rendering the results inapplicable to the diabetes population at large. Numerous studies have concluded that any increase in testing of blood glucose levels is likely to yield improvements in glycemic control, which raises questions as to whether any improvements observed in the clinical trials for insulin analogues were the result of more frequent testing or due to the drug undergoing trials.
In 2008, the Canadian Agency for Drugs and Technologies in Health (CADTH) found, in its comparison of the effects of insulin analogues and biosynthetic human insulin, that insulin analogues failed to show any clinically relevant differences, both in terms of glycemic control and adverse reaction profile.
- 1922 Banting and Best use bovine insulin extract on human
- 1923 Eli Lilly and Company (Lilly) produces commercial quantities of bovine insulin
- 1923 Hagedorn founds the Nordisk Insulinlaboratorium in Denmark forerunner of Novo Nordisk
- 1926 Nordisk receives Danish charter to produce insulin as a non-profit
- 1936 Canadians D.M. Scott and A.M. Fisher formulate zinc insulin mixture and license to Novo
- 1936 Hagedorn discovers that adding protamine to insulin prolongs the effect of insulin
- 1946 Nordisk formulates Isophane porcine insulin a.k.a. Neutral Protamine Hagedorn or NPH insulin
- 1946 Nordisk crystallizes a protamine and insulin mixture
- 1950 Nordisk markets NPH insulin
- 1953 Novo formulates Lente porcine and bovine insulins by adding zinc for longer-lasting insulin
- 1978 Genentech develop biosynthesis of recombinant human insulin in Escheria coli bacteria using recombinant DNA technology
- 1981 Novo Nordisk chemically and enzymatically converts porcine insulin to 'human' insulin (Actrapid HM)
- 1982 Genentech synthetic 'human' insulin approved, in partnership with Eli Lilly and Company, who shepherded the product through the U.S. Food and Drug Administration (FDA) approval process
- 1983 Lilly produces biosynthetic recombinant "rDNA insulin human INN" (Humulin)
- 1985 Axel Ullrich sequences the human insulin receptor
- 1988 Novo Nordisk produces synthetic, recombinant insulin ("insulin human INN")
- 1996 Lilly Humalog "insulin lispro INN" approved by the U.S. Food and Drug Administration
- 2003 Aventis Lantus "glargine" insulin analogue approved in USA 
- 2004 Sanofi Aventis Apidra insulin "glulisine" analogue approved in the USA.
- 2006 Novo Nordisk's Levemir "insulin detemir INN" analogue approved in the USA-
- 2013 Novo Nordisk's Tresiba "insulin degludec INN" analogue approved in Europe (EMA with additional monitoring]
- "Insulin Lispro: A Fast-Acting Insulin Analog". Retrieved 2007-06-08.
- "Aspart insulin (rDNA origin) injection". Archived from the original on 2007-06-10. Retrieved 2007-06-08.
- "Apidra insulin glulisine (rDNA origin) injection". Retrieved 2007-06-08.
- "Levemir insulin detemir (rDNA origin) injection". Retrieved 2007-06-08.
- Klein et al. "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability. Diabetes Obes Metab 2007 May;9(3):290-9
- Haahr H et Heise T: "A review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance" Clin Pharmacokinet (2014) 53:787-800
- "Lantus insulin glargine (rDNA origin) injection". Retrieved 2007-06-08.
- Owens DR, Bolli GB. 2008 Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. Oct;10(5):333-49.
- Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. 2012 Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012 Aug;29(8):2104-14.
- Zinman B. 2013 Newer insulin analogs: advances in basal insulin replacement. Diabetes Obes Metab. 2013 Mar;15 Suppl 1:6-10
- Conlon JM. 2001 Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships Peptides. 2001 Jul;22(7):1183-93
- Mayer JP, Zhang F, DiMarchi RD. 2007 Insulin structure and function. Biopolymers. 2007;88(5):687-713.
- Owens DR. 2011 Insulin preparations with prolonged effect. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S5-14.
- Horuk R, Blundell TL, Lazarus NR, Neville RW, Stone D, Wollmer A. 1980 A monomeric insulin from the porcupine (Hystrix cristata), an Old World hystricomorph. Nature Aug 21;286(5775):822-4.
- Tennagels N, Werner U. 2013 The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem. 2013 Feb;119(1):1-14.
- Varewijck AJ, Yki-Järvinen H, Schmidt R, Tennagels N, Janssen JA. 2013 Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling. Diabetes. 2013 Jul;62(7):2539-44.
- Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. 2012 Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28.
- Hanefeld M, Bramlage P. 2013 Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep. 2013 Jun;13(3):342-9.
- Horvath K, Jeitler K, Berghold A, Ebrahim Sh, Gratzer T, Plank J, Kaiser T, Pieber T, Siebenhofer A (2007). Horvath K, ed. "Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus". Cochrane Database of Systematic Reviews (2): CD005613. doi:10.1002/14651858.CD005613.pub3. PMID 17443605.
- Banerjee S, Tran K, Li H, Cimon K, Daneman D, Simpson S, Campbell K. "Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness," Technology Report No 87. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
- Glucose Control - Lantus receives FDA approval for flexible administration